Acumen price target lowered to $11 from $22 at BTIG

BTIG lowered the firm’s price target on Acumen to $11 from $22 but keeps a Buy rating on the shares after its Q4 results. The firm is updating its model to reflect the company’s updated trial timeline, though data to date suggest that ACU193 has the best-in-class safety profile, allowing for higher doses that improve efficacy without the high ARIA levels seen with other mAbs, the analyst tells investors in a research note.